[Long-term experience with prophylactic BCG therapy of high risk patients with superficial bladder tumors].

The authors analysed the data of 45 high risk patients with recurrent superficial transitional cell cancer of the bladder who received after radical transurethral resection prophylactic intracavitaly BCG treatment among 1987-1995. They observed complete remission (28/45), partial remission (10/45), non responders (7/45). The progression rate was (12/45).

[Immunotherapy of superficial bladder tumors in a hospital department].

Since 1988 27 patients with bladder cancer - in the T1, G1, G2 stage - have been treated by intra-cavitally applied BCG (Pasteur). The follow-up period was 12-62 months. There was no relapse in 18 cases (66%) in 4 cases (16%) increase the average relapse rate, in 5 cases the treatment was unsuccessful.